1. Home
  2. GOODN vs ERNAW Comparison

GOODN vs ERNAW Comparison

Compare GOODN & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gladstone Commercial Corporation

GOODN

Gladstone Commercial Corporation

N/A

Current Price

$22.32

Market Cap

0.0

Sector

Real Estate

ML Signal

N/A

Logo Ernexa Therapeutics Inc. Warrants

ERNAW

Ernexa Therapeutics Inc. Warrants

N/A

Current Price

$0.04

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GOODN
ERNAW
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2003
2021

Fundamental Metrics

Financial Performance
Metric
GOODN
ERNAW
Price
$22.32
$0.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.4K
30.3K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.29
EPS
0.18
N/A
Revenue
$161,336,000.00
$582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$124.44
N/A
Revenue Growth
8.00
N/A
52 Week Low
$20.91
$0.02
52 Week High
$23.91
$0.23

Technical Indicators

Market Signals
Indicator
GOODN
ERNAW
Relative Strength Index (RSI) 39.60 42.28
Support Level $22.03 $0.03
Resistance Level $22.67 $0.08
Average True Range (ATR) 0.33 0.02
MACD -0.13 -0.00
Stochastic Oscillator 25.62 0.47

Price Performance

Historical Comparison
GOODN
ERNAW

About GOODN Gladstone Commercial Corporation

Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.

About ERNAW Ernexa Therapeutics Inc. Warrants

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: